With its advanced offerings, Mammogen specializes in improving the detection, diagnosis, and treatment of breast cancer

NEWPORT BEACH, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Mammogen, a female-led predictive health company developing RNA-powered molecular diagnostics for women’s health, today appointed Elise Berman, M.D., as Chief Medical Officer. Dr. Berman brings more than two decades of leadership across breast imaging, medical affairs, and clinical development. She joins Mammogen as the company advances genTRU-breast™ through clinical validation and toward commercialization.

Mammogen has announced the successful completion of a Series A financing round of up to $30 million, marking a significant milestone in the company's mission to transform breast cancer detection through innovative blood-based diagnostics.